Trends in the Development of New Drugs for the Treatment of Benign Prostatic Hyperplasia
November 2006
in “
Current Medicinal Chemistry
”
α₁-adrenoceptor antagonists 5α-reductase inhibitors uroselective α₁-AR antagonists non-steroidal 5α-reductase inhibitors combined inhibitors endothelins androgen receptor antagonists growth factors estrogens phosphodiesterase isoenzymes phytomedicines alpha-1 blockers 5-alpha reductase inhibitors uroselective alpha-1 blockers non-steroidal 5-alpha reductase inhibitors androgen blockers PDE inhibitors herbal medicines
TLDR New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
The document from 2006 reviews the development of new drugs for the treatment of benign prostatic hyperplasia (BPH). It discusses the pharmacotherapy based on α₁-adrenoceptor (α₁-AR) antagonists and 5α-reductase inhibitors, which were the main treatments at the time. The review covers new α₁-AR antagonists and 5α-reductase inhibitors, including uroselective α₁-AR antagonists that aim to reduce side effects like hypotension, and non-steroidal 5α-reductase inhibitors with various chemical structures. It also explores combined inhibitors, endothelins, androgen receptor antagonists, growth factors, estrogens, phosphodiesterase isoenzymes, and phytomedicines. The document emphasizes the potential of these new agents in future drug development for BPH but does not provide specific study sizes or numeric values.
